Kostakoglu Lale, Goy Andre, Martinelli Giovanni, Caballero Dolores, Crump Michael, Gaidano Gianluca, Baetz Tara, Buckstein Rena, Fine Gregg, Fingerle-Rowson Guenter, Berge Claude, Sahin Deniz, Press Oliver, Sehn Laurie
a Department of Radiology , The Mount Sinai Hospital , New York , NY , USA.
b John Theurer Cancer Center HUMC , Hackensack , NJ , USA.
Leuk Lymphoma. 2017 Feb;58(2):372-381. doi: 10.1080/10428194.2016.1196815. Epub 2016 Jun 24.
An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0.25 (95%CI: 0.01-0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.
在II期GAUSS研究中，对75例接受奥妥珠单抗或利妥昔单抗诱导治疗（IT）4周的滤泡性淋巴瘤患者进行了探索性分析，旨在确定正电子发射断层扫描（PET）结果是否能够预测无进展生存期（PFS）和肿瘤反应。IT后PET呈阳性的患者（使用多维尔五点量表标准评估；35/52，67%）发生PFS事件（进展或死亡）的比例高于PET呈阴性的患者（5/20，25%）；进展或死亡的风险比为0.25（95%CI：0.01 - 0.64；p = 0.0018）。当使用国际协调项目和欧洲癌症研究与治疗组织标准评估PET结果时，也发现了显著相关性。IT基线与结束时标准化摄取值及其他PET参数值的变化与PFS和反应相关。有必要在更大队列的前瞻性研究中验证这些结果。
